I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Switzerland

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Infectious Disease COVID-19

COVID-19

What's new

Sign up or login to unlock the full suite of MEDICALLY features
Sep 18 / Roche
Evaluation of T cell responses detected by the Elecsys IGRA SARS-CoV-2 assay
This study aimed to determine the clinical performance of the Elecsys IGRA SARS-CoV-2 assay to detect SARS-CoV-2-specific T cell responses upon natural infections or vaccinations.
Infectious Disease COVID-19 ESCV-2024

Sign up or login to unlock the full suite of MEDICALLY features
Aug 27 / Roche
Real-world trends in SARS-CoV-2 antibody levels and their link to subsequent COVID-19 in the United States
Study is to assess the SARS-CoV-2 antibody levels over time (2021-2022), measured with the Elecsys Anti-SARS-COV-2 S assay, in the real-world setting, and assess the association between them and subsequent COVID-19 outcomes.
Infectious Disease COVID-19 ISPE-2024

Sign up or login to unlock the full suite of MEDICALLY features
May 6 / Roche and Genentech
The Impact of Funding Tocilizumab for the Inpatient Treatment of COVID-19 in the United States: A Distributional Cost-Effectiveness Analysis
We conducted a distributional cost-effectiveness analysis to evaluate how coverage of tocilizumab for inpatients with COVID-19 from 2021 to present impacted health equity in the United States. Tocilizumab treatment was cost-effective across all subgroups. Treatment resulted in larger relative QALY gains in more socially vulnerable subgroups than less socially vulnerable subgroups, given higher hospitalization rates and inpatient mortality. Future equitable access to tocilizumab for inpatients with COVID-19 is expected to lead to continued increases in population health and reductions in disparities.
Infectious Disease COVID-19 ISPOR-2024

Sign up or login to unlock the full suite of MEDICALLY features
May 6 / Roche and Genentech
Higher Sars-Cov-2 Spike Antibody Levels Are Associated with Reduced Risk of Subsequent Symptomatic and Severe COVID-19: A Real-World Data Study
This was a retrospective cohort study using data linkage to assess the protective effect of antibody titers against SARS-CoV-2-infection. The study demonstrated a strong association between spike antibody levels and the subsequent risk of developing COVID-19.
Infectious Disease COVID-19 ISPOR-2024

Sign up or login to unlock the full suite of MEDICALLY features
Apr 27 / Roche
Real-world evidence comparing the risk of Delta and Omicron infection outcomes by SARS-CoV-2 antibody levels
This study aimed to use real-world data to explore the association between ACOV2S antibody titre levels and the risk of COVID-19-related outcomes (symptomatic and severe), pre- and post-Omicron occurrence.
Infectious Disease COVID-19 ESCMID-2024

Sign up or login to unlock the full suite of MEDICALLY features
Jun 26 / Roche
Unveiling the potential of T cell response monitoring in the changing landscape of the SARS-CoV-2 pandemic
This webinar discusses the potential role T cell responses in the changing landscape of the SARS-CoV-2 pandemic. The speakers discuss the contribution of T cell responses to vaccine protection against severe COVID-19 disease, particularly in immunocompromised individuals and against viral variants that partially escape recognition by neutralizing antibodies (NAbs). Information about methods available to measure T cell responses as well as use cases will be discussed based on up-to-date scientific knowledge.
Infectious Disease COVID-19 IRIDS-2022
Upcoming Congress
Access to Roche and Genentech's latest medical information
View related congresses

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.